Celiac Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Celiac Disease remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 129 matched trial records and 44 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07701655 | Intervention not normalized | Not Applicable; Not yet recruiting | The Cleveland Clinic Foundation | Geography not listed | Aim 1 Prediction Model (1 year); Aim 2 Interview Transcript Coding (Years 2-3) | 2030-12-01 |
| NCT07585669 | Intervention not normalized | Not Applicable; Recruiting | University of Chile | Chile | Modulation of systemic inflammatory response via cytokine levels and NF-κB signaling in peripheral blood mononuclear cells (From baseline (T0) to 3 months (T3) of supplementation) | 2026-10-30 |
| NCT07584473 | Intervention not normalized | Not Applicable; Recruiting | University of Palermo | Italy | Identification of patients with self-reported NCWS or IBS/FD not related to wheat intake among relatives of CD patients: Gastrointestinal Symptom Rating Scale (GSRS) (From baseline to 6-week) | 2027-04-30 |
| NCT07578038 | Intervention not normalized | Not Applicable; Not yet recruiting | Fondation Lenval Nice | France | Compare the 1-year effectiveness of a clinical follow-up strategy based on urinary GIP measurement versus standard care, in patients with celiac disease in the pediatric population. (12 month) | 2029-06-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease (Phase 2): the indexed record reports Changes From Baseline in Villous Height to Crypt Depth (Vh:Cd) as Assessed by Esophagogastroduodenoscopy With Biopsy After 2-week Gluten Challenge (GC)(Mean) = -0.61 ratio (Standard Deviation, 0.614); Changes From Baseline in Villous Height to Crypt Depth (Vh:Cd) as Assessed by Esophagogastroduodenoscopy With Biopsy After 2-week Gluten Challenge (GC)(Mean): Least Squares Mean Difference = -0.26(95% CI, -0.63 to 0.11), P-Value = 0.1668; Changes From Baseline in Villous Height to Crypt Depth (Vh:Cd) as Assessed by Esophagogastroduodenoscopy With Biopsy After 2-week Gluten Challenge (GC)(Mean) = -0.85 ratio (Standard Deviation, 0.707).
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients With Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet (Phase 2): the indexed record reports Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24(Least Squares Mean) = -1.32 score on a scale (95% Confidence Interval, -1.66 to -0.98); Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24(Least Squares Mean): Least square (LS) mean difference = 0.04(95% CI, -0.43 to 0.52), P-Value = 0.8543; LS mean difference = 0.11(95% CI, -0.37 to 0.59), P-Value = 0.6552; LS mean difference = 0.04(95% CI, -0.45 to 0.53), P-Value = 0.8705; Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24(Least Squares Mean) = -1.28 score on a scale (95% Confidence Interval, -1.62 to -0.94).
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet (Phase 2): the indexed record reports Change in Weekly Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) Symptom Severity Score From Baseline to Week 12(Least Squares Mean): LS Mean Difference = 0.017(95% CI, -0.162 to 0.197), P-Value = 0.847; Change in Weekly Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) Symptom Severity Score From Baseline to Week 12(Least Squares Mean) = -0.128 score on a scale (Standard Error, 0.083); Change in Weekly Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) Symptom Severity Score From Baseline to Week 12(Least Squares Mean): LS Mean Difference = 0.017(95% CI, -0.162 to 0.197), P-Value = 0.847.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including The selected trials include interventions that are not yet normalized to an asset record. Company & Deal Intelligence records identify sponsor context for The Cleveland Clinic Foundation, University of Chile, University of Palermo, Fondation Lenval Nice. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Celiac Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
